The agency published a guideline for the implementation of ICH Q3D.
On August 4, 2016, the European Directorate for the Quality of Medicines & HealthCare (EDQM) published
Implementation of ICH Q3D in the Certification Procedureto provide guidance on the implementation of the International Council for Harmonization’s (ICH) Q3D Guideline for Elemental Impurities as it applies to Certificates of Suitability (CEP). The new EDQM guidance applies to both new and existing CEPs.
EDQM’s policy for elemental impurities covered by a CEP to the monographs of the European Pharmacopoeia (Ph.Eur.), in relation to substances within the scope of ICH Q3D, is detailed in the new guidance. The guidance explains the implementation of the policy, which includes providing a risk management summary (RMS) for elemental impurities that may be present in the manufacturing process of the final substance. EDQM provides instructions on how to build an RMS and how to define a control strategy. The guidance also details what information should be provided on the CEP.
ICH Q3D, which went into effect in the European Union in June 2016 for new marketing authorization applications and applies to authorized medicinal products starting in December 2017, emphasizes a risk-based approach to limiting elemental impurities. It addresses 24 elements and provides permitted daily exposure limits. ICH Q3D considers multiple aspects of manufacturing including equipment, water, and container-closure systems.
Source: EDQM
EMA Recommends Imfinzi-Based Perioperative Regimen for Treating Resectable NSCLC
March 10th 2025The committee’s recommendation is based on results from a Phase III trial in which Imfinzi demonstrated a reduced risk of recurrence, progression, or death by 32% compared to neoadjuvant chemotherapy alone.
International Women’s Day 2025: A Promising Future for Gender Diversity in Pharma
March 8th 2025In an interview with BioPharm International®, Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.